TY - JOUR
T1 - Expression of amino acid transporter (LAT1 and 4F2hc) in pulmonary pleomorphic carcinoma
AU - Kaira, Kyoichi
AU - Kawashima, Osamu
AU - Endoh, Hedeki
AU - Imaizumi, Kazuyoshi
AU - Goto, Yasuhiro
AU - Kamiyoshihara, Mitsuhiro
AU - Sugano, Masayuki
AU - Yamamoto, Ryohei
AU - Osaki, Takashi
AU - Tanaka, Shigefumi
AU - Fujita, Atsushi
AU - Imai, Hisao
AU - Kogure, Yoshihito
AU - Seki, Yukio
AU - Shimizu, Kimihiro
AU - Mogi, Akira
AU - Shitara, Yoshinori
AU - Oyama, Tetsunari
AU - Kanai, Yoshikatsu
AU - Asao, Takayuki
N1 - Publisher Copyright:
© 2018 Elsevier Inc.
Copyright:
Copyright 2019 Elsevier B.V., All rights reserved.
PY - 2019/2
Y1 - 2019/2
N2 - Amino acid transporters are necessary for tumor growth, metastasis, and survival of various neoplasms; however, the clinicopathological significance of L-type amino acid transporter 1 (LAT1) and 4F2 cell surface antigen (4F2hc) in patients with pulmonary pleomorphic carcinoma (PPC) remainsunknown. The aim of this study is to clarify the prognostic impact of these amino acid transporters in PPC. One hundred five patients with surgically resected PPC were assessed by immunohistochemistry. The expression of LAT1 and 4F2hc, and Ki-67 labeling index were investigated using specimens of the resected tumors. LAT1 and 4F2hc were highly expressed in 35% and 53% of all patients (n = 105, P <.01), 25% and 48% of patients with an adenocarcinoma component (n = 48, P =.02), and 44% and 58% of patients with a nonadenocarcinoma component (n = 57, P =.18), respectively. A high LAT1 expression was significantly related to advanced disease, lymphatic permeation, tumor cell proliferation, and 4F2hc expression. By multivariate analysis, LAT1 and 4F2hc were identified as significant independent markers for predicting a worse prognosis. LAT1 is highly expressed in PPC, and high LAT1 expression can serve as a significant predictor linked to a worse prognosis in patients with PPC.
AB - Amino acid transporters are necessary for tumor growth, metastasis, and survival of various neoplasms; however, the clinicopathological significance of L-type amino acid transporter 1 (LAT1) and 4F2 cell surface antigen (4F2hc) in patients with pulmonary pleomorphic carcinoma (PPC) remainsunknown. The aim of this study is to clarify the prognostic impact of these amino acid transporters in PPC. One hundred five patients with surgically resected PPC were assessed by immunohistochemistry. The expression of LAT1 and 4F2hc, and Ki-67 labeling index were investigated using specimens of the resected tumors. LAT1 and 4F2hc were highly expressed in 35% and 53% of all patients (n = 105, P <.01), 25% and 48% of patients with an adenocarcinoma component (n = 48, P =.02), and 44% and 58% of patients with a nonadenocarcinoma component (n = 57, P =.18), respectively. A high LAT1 expression was significantly related to advanced disease, lymphatic permeation, tumor cell proliferation, and 4F2hc expression. By multivariate analysis, LAT1 and 4F2hc were identified as significant independent markers for predicting a worse prognosis. LAT1 is highly expressed in PPC, and high LAT1 expression can serve as a significant predictor linked to a worse prognosis in patients with PPC.
UR - http://www.scopus.com/inward/record.url?scp=85059858167&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85059858167&partnerID=8YFLogxK
U2 - 10.1016/j.humpath.2018.09.020
DO - 10.1016/j.humpath.2018.09.020
M3 - Article
C2 - 30300664
AN - SCOPUS:85059858167
VL - 84
SP - 142
EP - 149
JO - Human Pathology
JF - Human Pathology
SN - 0046-8177
ER -